Table 2.
Comparison of QOL baseline score with published data [17] EORTC QLQ-C30 and BN20 scales and items. Presented with mean score, standard deviation and median scores
| Variable | Nwachukwu et. al Mean (SD) |
Median (IQR) | Deroger et al [17] Mean (SD) |
|---|---|---|---|
| QLQ-C30 domaina | |||
|
| |||
| Global | 78 (18) | 83 (67-92) | 76.4 (22.8) |
| Functional Scales | |||
| Physical | 92(21) | 100(93-100) | 88.0 (18.3) |
| Role | 91(23) | 100(100-100) | 88.2 (23.9) |
| Emotional | 80(23) | 83(67-100) | 85.8 (18.7) |
| Cognitive | 84(21) | 83(83-100) | 88.1 (16.9) |
| Social | 87(25) | 100(83-100) | 91.2 (19.0) |
| Symptoms Scales | |||
| Fatigue | 17(20) | 11(0-22) | 19.1 (21.7) |
| Nausea/Vomiting | 2(7) | 0(0-0) | 2.6 (9.3) |
| Pain | 10(21) | 17(0-17) | 18.9 (25.7) |
| Dyspnea | 7(16) | 0(0-0) | 16.3 (24.3) |
| Insomnia | 15(23) | 0(0-33) | 17.5 (25.9) |
| Appetite Loss | 6(18) | 0(0-0) | 3.3 (12.8) |
| Constipation | 8(20) | 0(0-0) | 5.4 (6.1) |
| Diarrhea | 7(18) | 0(0-0) | 5.6 (15.9) |
| Financial | 16(29) | 0(0-33) | 4.4 (16.2) |
| QLQ-BN20 domain b | |||
| Overall | 12(14) | 7(2-15) | |
| Future Uncertainty | 0(0.17) | 0(0-0.17) | |
| Visual Disorders | 9(18) | 0(0-11) | |
| Motor Dysfunction | 15(25) | 0(0-22) | |
| Communication Difficulty | 15(23) | 0(0-22) | |
| Headaches | 17(22) | 0(0-33) | |
| Seizures | 5(16) | 0(0-0) | |
| Drowsiness | 20(25) | 0(0-0) | |
| Itchy Skin | 8(19) | 0(0-0) | |
| Hair Loss | 9(21) | 0(0-0) | |
| Weak Legs | 8(23) | 0(0-0) | |
| Bladder Control | 9(25) | 0(0-0) | |
a
For QLQ-C30 functional subscales -higher values reflect higher functioning or better quality of life; symptom subscales- lower scores reflect less symptomatology.
b
For BN-20 domain, higher scores reflect greater degree of dysfunction